Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma

Resistance to conventional chemotherapeutic agents, a typical feature of cholangiocarcinoma, prevents the efficacy of the therapeutic arsenal usually used to combat malignancy in humans. Mechanisms of chemoresistance by neoplastic cholangiocytes include evasion of drug-induced apoptosis mediated by autocrine and paracrine cues released in the tumor microenvironment. Here, recent evidence regarding molecular mechanisms of chemoresistance is reviewed, as well as associations between well-developed chemoresistance and activation of the cancer stem cell compartment. It is concluded that improved understanding of the complex interplay between apoptosis signaling and the promotion of cell survival represent potentially productive areas for active investigation, with the ultimate aim of encouraging future studies to unveil new, effective strategies able to overcome current limitations on treatment.

[1]  Yusuke Nakamura,et al.  Enhanced Expression of RAD51 Associating Protein-1 Is Involved in the Growth of Intrahepatic Cholangiocarcinoma Cells , 2008, Clinical Cancer Research.

[2]  R. Wells,et al.  Lineage tracing demonstrates no evidence of cholangiocyte epithelial‐to‐mesenchymal transition in murine models of hepatic fibrosis , 2011, Hepatology.

[3]  Sara R. Selitsky,et al.  Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells , 2015, Nature Communications.

[4]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[5]  A. Franchitto,et al.  Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. , 2006, The American journal of pathology.

[6]  Z. Estrov,et al.  Leukemia‐inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways , 1996, International journal of cancer.

[7]  Jeong-Seok Nam,et al.  Cancer stem cells: the 'Achilles heel' of chemo-resistant tumors. , 2014, Recent patents on anti-cancer drug discovery.

[8]  R. Sakai,et al.  Direct Interaction between Carcinoma Cells and Cancer Associated Fibroblasts for the Regulation of Cancer Invasion , 2015, Cancers.

[9]  C. Spirlí,et al.  Pathophysiology of cholangiopathies. , 2005, Journal of clinical gastroenterology.

[10]  S. Chien,et al.  Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis , 2016, Proceedings of the National Academy of Sciences.

[11]  G. Gores,et al.  The Anti-apoptotic Protein Mcl-1 Inhibits Mitochondrial Ca2+ Signals* , 2005, Journal of Biological Chemistry.

[12]  B. Jang,et al.  Clinicopathologic Significance of Sox2, CD44 and CD44v6 Expression in Intrahepatic Cholangiocarcinoma , 2014, Pathology & Oncology Research.

[13]  R. Tohtong,et al.  CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2 , 2013, Oncology letters.

[14]  S. Chaney,et al.  Protein interactions with platinum-DNA adducts: from structure to function. , 2004, Journal of inorganic biochemistry.

[15]  C. Cordon-Cardo,et al.  Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.

[16]  C. Desbois-Mouthon,et al.  Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor , 2013, Hepatology.

[17]  A. Floreani,et al.  Epidemiological aspects of biliary tree tumors in a region of northern Italy: emerging trends and sex-based differences , 2013, European journal of gastroenterology & hepatology.

[18]  M. Elkind Epidemiology and Risk Factors , 2011, Continuum.

[19]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  D. Schuppan,et al.  Macrophage recruitment by fibrocystin‐defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis , 2016, Hepatology.

[21]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[22]  Zhiwei Wang,et al.  Emerging roles of PDGF-D signaling pathway in tumor development and progression. , 2010, Biochimica et biophysica acta.

[23]  Yangde Zhang,et al.  Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells , 2011, Molecular Cancer.

[24]  T. Yang,et al.  Insights into Chemoresistance of Prostate Cancer , 2015, International journal of biological sciences.

[25]  H. Pinedo,et al.  Anti‐tumor activity of CPT‐11 in experimental human ovarian cancer and human soft‐tissue sarcoma , 1997, International journal of cancer.

[26]  J. Mott,et al.  XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells , 2014, PloS one.

[27]  W L Allen,et al.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.

[28]  Katrin Wlcek,et al.  The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer , 2011, Cancer biology & therapy.

[29]  A. Diehl,et al.  Hedgehog signaling in cholangiocytes , 2011, Current opinion in gastroenterology.

[30]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[31]  R. Franke,et al.  Pharmacogenetics of the organic anion transporting polypeptide 1A2. , 2009, Pharmacogenomics.

[32]  K. Shiraki,et al.  Cellular FLICE/Caspase-8–Inhibitory Protein as a Principal Regulator of Cell Death and Survival in Human Hepatocellular Carcinoma , 2003, Laboratory Investigation.

[33]  R. Qin,et al.  CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells , 2011, International journal of cancer.

[34]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[35]  John Calvin Reed,et al.  The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Gores,et al.  GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis , 2010, Oncogene.

[37]  G. Carpino,et al.  Cholangiocarcinoma: Epidemiology and risk factors , 2011 .

[38]  Y. Lo,et al.  Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers , 2015, Oncotarget.

[39]  M. Vogler Targeting BCL2-Proteins for the Treatment of Solid Tumours , 2014, Advances in medicine.

[40]  H. Thomas,et al.  p53 mutations in human cholangiocarcinoma: a review , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[41]  S. Fulda Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). , 2014, Advances in experimental medicine and biology.

[42]  Makiko Takahashi,et al.  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins , 2010, Breast Cancer Research.

[43]  M. Ogawa,et al.  Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways , 1997, International journal of cancer.

[44]  O. Briz,et al.  Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib , 2013, Hepatology.

[45]  T. Pawlik,et al.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.

[46]  Xin Zeng,et al.  Inhibition of Wnt/β‐catenin signaling downregulates P‐glycoprotein and reverses multi‐drug resistance of cholangiocarcinoma , 2013, Cancer science.

[47]  D. Goldstein,et al.  Role of pancreatic stellate cells in chemoresistance in pancreatic cancer , 2014, Front. Physiol..

[48]  J. Marin,et al.  Molecular Bases of Chemoresistance in Cholangiocarcinoma. , 2017, Current drug targets.

[49]  L. Fabris,et al.  Development of the bile ducts: essentials for the clinical hepatologist. , 2012, Journal of hepatology.

[50]  T. Burnouf,et al.  Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment , 2014, Cancer growth and metastasis.

[51]  Michael Karin,et al.  NF-kappaB in cancer: a marked target. , 2003, Seminars in cancer biology.

[52]  S. Vickers,et al.  Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. , 1997, Cancer research.

[53]  G. Gores,et al.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.

[54]  J. Panyam,et al.  CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[55]  W. Tassaneeyakul,et al.  Characterization of 5-Fluorouracil-Resistant Cholangiocarcinoma Cell Lines , 2008, Chemotherapy.

[56]  C. Pairojkul,et al.  Periostin activates integrin α5β1 through a PI3K/AKT‑dependent pathway in invasion of cholangiocarcinoma. , 2012, International journal of oncology.

[57]  Tara Karnezis,et al.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.

[58]  Michael Karin,et al.  NF-κB in cancer: a marked target , 2003 .

[59]  Lei-bo Xu,et al.  Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. , 2014, Oncology reports.

[60]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[61]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[62]  M. Manns,et al.  A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.

[63]  G. Gores,et al.  Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.

[64]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[65]  R. Fiorotto,et al.  Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. , 2013, Clinics and research in hepatology and gastroenterology.

[66]  B. Wolpin,et al.  A step forward in the treatment of advanced biliary tract cancer. , 2010, The New England journal of medicine.

[67]  D. Seehofer,et al.  Hedgehog pathway as a potential treatment target in human cholangiocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.

[68]  B. Guillotin,et al.  The LIF cytokine: towards adulthood. , 2009, European cytokine network.

[69]  T. Kisseleva,et al.  Is it the end of the line for the EMT? , 2011, Hepatology.

[70]  P. Heinrich,et al.  Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells , 2005, Journal of Cell Science.

[71]  N. Samadi,et al.  Tumor microenvironment-mediated chemoresistance in breast cancer. , 2016, Breast.

[72]  G. Gores,et al.  Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. , 2005, Gastroenterology.

[73]  M. Aglietta,et al.  Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient , 2015, Tumor Biology.

[74]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[75]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[76]  L. Fabris,et al.  Epithelial-mesenchymal interactions in biliary diseases. , 2011, Seminars in liver disease.

[77]  J. Marin Plasma Membrane Transporters in Modern Liver Pharmacology , 2012, Scientifica.

[78]  G. Semenza,et al.  Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.

[79]  F. Giuliante,et al.  Profiles of cancer stem cell subpopulations in cholangiocarcinomas. , 2015, The American journal of pathology.

[80]  A. Bauer,et al.  YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors , 2015, Hepatology.

[81]  S. Nagata,et al.  Fas‐mediated cholangiopathy in the murine model of graft versus host disease , 2000, Hepatology.

[82]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[83]  Y. Nakanuma,et al.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease , 2008, Proceedings of the National Academy of Sciences.

[84]  K. Watabe,et al.  Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition , 2013, OncoTargets and therapy.

[85]  Yabing Chen,et al.  Structural and Biophysical Characterization of the Interactions between the Death Domain of Fas Receptor and Calmodulin* , 2013, The Journal of Biological Chemistry.

[86]  T. Patel,et al.  Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. , 2006, Journal of hepatology.

[87]  T. Utsunomiya,et al.  Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. , 2011, Hepato-gastroenterology.

[88]  R. Qin,et al.  Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell‐like properties , 2011, International journal of cancer.

[89]  G. Gores,et al.  Myofibroblast‐derived PDGF‐BB promotes hedgehog survival signaling in cholangiocarcinoma cells , 2011, Hepatology.

[90]  G. Gores,et al.  Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.

[91]  S. Moriyama,et al.  Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.

[92]  Rachelle W Johnson,et al.  Leukemia inhibitory factor: A paracrine mediator of bone metabolism , 2012, Growth factors.

[93]  A. Franchitto,et al.  An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[94]  R. Fiorotto,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Protein Kinase A-Dependent pSer-b-catenin, a Novel Signaling Defect in a Mouse Model of Congenital Hepatic Fibrosis , 2013 .

[95]  Yinping Tong,et al.  Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma , 2015, Oncotarget.

[96]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[97]  K. Torgersen,et al.  Human Naturally Occurring and Adaptive Regulatory T cells Secrete High Levels of Leukaemia Inhibitory Factor upon Activation , 2008, Scandinavian journal of immunology.

[98]  E. Gaudio,et al.  Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[99]  R. Fiorotto,et al.  Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma , 2013, Hepatology.

[100]  Jorge A. Almenara,et al.  Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. , 2014, Experimental and molecular pathology.

[101]  L. Aghajanova Leukemia Inhibitory Factor and Human Embryo Implantation , 2004, Annals of the New York Academy of Sciences.

[102]  Dong-Yan Shen,et al.  β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma. , 2015, World journal of gastroenterology.

[103]  F. Zouein,et al.  LIF and the heart: just another brick in the wall? , 2013, European cytokine network.

[104]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[105]  P. Dubus,et al.  Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution , 2016, Oncotarget.

[106]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[107]  LIF-Dependent Signaling: New Pieces in the Lego , 2011, Stem Cell Reviews and Reports.

[108]  J. Neuberger,et al.  Characterization and isolation of ductular cells coexpressing neural cell adhesion molecule and Bcl-2 from primary cholangiopathies and ductal plate malformations. , 2000, The American journal of pathology.

[109]  M. Manns,et al.  Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma , 2013, Hepatology.

[110]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[111]  S. Groshen,et al.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  M. Selvakumaran,et al.  Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. , 2003, Cancer research.

[113]  M. Poupon,et al.  CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.

[114]  Yan Liu,et al.  Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. , 2015, European journal of medicinal chemistry.

[115]  G. Gores,et al.  Polo‐like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma , 2013, Hepatology.

[116]  H. Hong,et al.  Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. , 2011, Biochemical and biophysical research communications.

[117]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[118]  Justin L. Mott,et al.  miR‐25 targets TNF‐related apoptosis inducing ligand (TRAIL) death receptor‐4 and promotes apoptosis resistance in cholangiocarcinoma , 2012, Hepatology.

[119]  Christine Otway Just another brick in the wall , 2007 .

[120]  A. Franchitto,et al.  Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. , 2000, Gastroenterology.

[121]  L. Fabris,et al.  Notch signaling in hepatocellular carcinoma: guilty in association! , 2012, Gastroenterology.

[122]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[123]  H. Baba,et al.  Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice , 2016, Hepatology.

[124]  T. Takayama,et al.  Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-π-Specific Inhibitor O1-Hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester , 2003, Journal of Pharmacology and Experimental Therapeutics.

[125]  T. Wang,et al.  Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.

[126]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[127]  C. Tiribelli,et al.  The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study , 2013, PloS one.

[128]  G. Gores,et al.  Inhibition of interleukin 6–mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line , 1999, Hepatology.

[129]  G. Gores Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.

[130]  I. Hwang,et al.  Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients , 2011, Cancer Chemotherapy and Pharmacology.

[131]  Thomas Kirchner,et al.  Migrating cancer stem cells — an integrated concept of malignant tumour progression , 2005, Nature Reviews Cancer.

[132]  G. Wong,et al.  Hyaluronan-CD44v3 Interaction with Oct4-Sox2-Nanog Promotes miR-302 Expression Leading to Self-renewal, Clonal Formation, and Cisplatin Resistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma* , 2012, The Journal of Biological Chemistry.

[133]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[134]  W. Hung,et al.  Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. , 2013, Oncology reports.

[135]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[136]  S. Dupont,et al.  The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.

[137]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[138]  Hongxiang Liu,et al.  CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma , 2011, BMC Cancer.

[139]  M. Serrano,et al.  No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. , 2012, Molecular pharmaceutics.

[140]  G. Gores,et al.  Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.

[141]  R. Hynes,et al.  The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.

[142]  A. Floreani,et al.  Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation , 2015, Oncotarget.

[143]  T. Utsunomiya,et al.  CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma , 2010, Journal of Gastroenterology.

[144]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[145]  James B. Mitchell,et al.  Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF‐κB , 2000, Head & neck.

[146]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[147]  Li Xing Advances in pathogenesis,diagnosis and treatment strategies of food allergy , 2014 .

[148]  L. Fabris,et al.  Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. , 2013, Translational gastrointestinal cancer.

[149]  S. Dupont,et al.  Molecular Pathways Molecular Pathways : YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis , 2013 .

[150]  R. Rousseau,et al.  Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. , 2011, Anticancer research.

[151]  M. Alison Liver stem cells , 2007, Stem Cell Reviews.

[152]  N. Khuntikeo,et al.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. , 2012, World journal of gastroenterology.

[153]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.

[154]  H. Van Vlierberghe,et al.  Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. , 2016, Journal of hepatology.

[155]  G. Gores,et al.  Bcl‐2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line , 1997, Hepatology.

[156]  Ricardo J. Ferreira,et al.  P-glycoprotein and membrane roles in multidrug resistance. , 2015, Future medicinal chemistry.

[157]  P. Johnston,et al.  Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.

[158]  G. Chalkiadakis,et al.  Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? , 2001, The Journal of surgical research.

[159]  Shufeng Zhou,et al.  Molecular mechanisms for tumour resistance to chemotherapy , 2016, Clinical and experimental pharmacology & physiology.

[160]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[161]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[162]  A. Paradiso,et al.  Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer , 2001, British Journal of Cancer.

[163]  J. Llovet,et al.  Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. , 2012, Gastroenterology.

[164]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[165]  F. Dufour,et al.  Death receptors as targets in cancer , 2013, British journal of pharmacology.

[166]  Kaiming Wu,et al.  MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. , 2016, Gene.

[167]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[168]  R. Pochampally,et al.  Human multipotent stromal cells from bone marrow and microRNA: Regulation of differentiation and leukemia inhibitory factor expression , 2008, Proceedings of the National Academy of Sciences.

[169]  G. Gores,et al.  Classification, diagnosis, and management of cholangiocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[170]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[171]  K. Mimori,et al.  CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.

[172]  R. Edwards,et al.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer , 2013, Disease Models & Mechanisms.

[173]  J. Becker,et al.  Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. , 2009, Cancer research.

[174]  H. Gascan,et al.  Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. , 2007, Blood.

[175]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[176]  A. Sica,et al.  Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. , 2017, Journal of hepatology.

[177]  R. Tohtong,et al.  Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. , 2011, International journal of oncology.

[178]  S. Aebi,et al.  The role of DNA mismatch repair in drug resistance. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[179]  M. Strazzabosco,et al.  Emerging roles of Notch signaling in liver disease , 2015, Hepatology.

[180]  A. Sabichi,et al.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. , 2013, Blood.

[181]  H. Baba,et al.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma , 2010, Cancer science.